Citations

Clear

1575 citation(s) found for "Im, Gene".

Gene Expression Profiling of Hyperdiploid Multiple Reveal Complex Gene Dosage Effects and an mRNA Translation/Protein Synthesis Signature.
Wier, Scott Van, Ahmann, Gregory , Price-Troska, Tammy, Henderson, Kim, Chesi, Marta , Chung, Tae-Hoon , Carpten, John D. , Lacy, Martha Q. , Kyle, Robert A. , Greipp, Philip R., Chng, Wee Joo , Price-Troska, Tammy, Henderson, Kimberly J., Kim, Seungchan , Gertz, Morie A. , Rajkumar, S. Vincent , Dispenzieri, Angela , Bergsagel, P. Leif , Fonseca, Rafaël

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 1538-1538

10.1182/blood.v106.11.1538.1538 Get It

Abstract Hyperdiploid MM (H-MM), characterized by recurrent trisomies constitute about 50% of MM, yet very little is known about its pathogenesis and oncogenic mechanisms. Studies in leukemia and solid tumors have shown gene dosage effect of aneuploidy on gene expression. To determine the possible gene dosage effect and deregulated cellular program in H-MM we undertook a gene expression study of CD138-enriched plasma-cell RNA from 53 hyperdiploid and 37 non-hyperdiploid MM (NH-MM) patients using the Affymetrix U133A chip (Affymetrix, Santa Clara, CA). Gene expression data was analyzed using GeneSpring 7 (Agilent Technologies, Palo Alto, CA). Genes differentially expressed between H-MM and NH-MM were obtained by t-test (p<0.01). The majority of the differentially expressed genes (57%) were under-expressed in H-MM. Genes located on the commonly trisomic chromosomes were mostly (but not always) over-expressed in H-MM and constitute 76% of over-expressed genes. Chromosome 1 contained the most differentially expressed genes (17%) followed by chromosome 12 (9%), and 19 (8%). To examine the relationship of gene copy number to gene expression, we examined the expression of genes on chromosomes 9 and 15 in subjects with 2 copies (15 normal control and 20 NH-MM) and 3 copies (12 H-MM) of each chromosome as detected by interphase FISH. We then derived a ratio of the mean expression of each gene on these chromosomes between patients with 3 copies and 2 copies of the chromosome. If a simple relationship exists between gene expression and gene copy number, one would expect the ratio of expression of most genes on these two chromosomes to be about 1.5 in H-MM compared to NH-MM. However, many genes have ratios either higher than 2 or lower than 0.5. Furthermore, when the heterogeneity of cells with underlying trisomies is taken into consideration by correcting the ratio for the number of cells with trisomies, the actual ratio is always lower than the expected ratio. When the expression of genes on a chromosome was compressed to a median value, this value was always higher in the trisomic chromosomes for H-MM compared to NH-MM. The data suggests that although gene dosage influence gene expression, the relationship is complex and some genes are more gene dosage dependent than others. Amongst the differentially expressed genes with known function, 33% are involved in mRNA translation/protein synthesis. Of note, 37 of the top 100 differentially expressed genes are involved in these processes. In particular, 60 ribosomal protein (RP) genes are significantly (p<0.05) upregulated in H-MM. This signature in H-MM is not associated with increase proliferation as measured by PCLI. This predominant signature suggests that deregulated protein synthesis may be important for the biology of H-MM. Many of these RPs are involved in the synthesis of product of oncogenic pathways (e.g. MYC, NF-KB pathways) and may mediate the growth and survival of tumor cells. It is therefore possible that these tumor cells may be sensitive to the disruption of mRNA translation/protein synthesis. Targeting the mTOR pathway with rapamycin may therefore be useful for treatment of H-MM.
Gene Expression Profiling of Myeloma Cells at Diagnosis Can Predict Response to Therapy with Thalidomide and Dexamethasone Combination.
Kumar, Shaji , Greipp, Philip R., Haug, Jessica, Kline, Michael, Blood, Emily, Bergsagel, Leif, Lust, John A., Chng, Wee Joo , Bergsagel, P. Leif , Gertz, Morie A. , Fonseca, Rafaël , Rajkumar, S. Vincent

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 508-508

10.1182/blood.v106.11.508.508 Get It

Abstract Background: Thalidomide and dexamethasone combination has been shown to be an effective therapy for multiple myeloma (MM). In newly diagnosed patients with MM, the combination results in overall response rates of over 70% of patients. However, a considerable number of patients do not respond and will need to proceed to other therapies. The ability to identify patients who are unlikely to respond to particular therapies will allow tailoring of therapeutic approaches and in turn will reduce unnecessary toxicity and morbidity from lack of rapid disease control. With the availability of new technology such as gene expression profiling (GEP), this has become a possibility. We employed this approach to identify genes that can reliably predict lack of response to the thalidomide dexamethasone combination. Methods: Patient samples from the Eastern Co-operative Oncology Group clinical trial (E1A00), that compared thalidomide-dexamethasone combination with dexamethasone, and patient samples from the phase II Mayo Clinic study of thalidomide and dexamethasone, both for newly diagnosed MM, were used for this study. Thirty newly diagnosed patients who were evaluable for response were included in the analysis. GEP was performed using the Affymetrix U133A microarray platform as per manufacturer’s recommendation. The Affymetrix output (CEL files) was imported into Genespring 7.2 (Agilent Technologies) microarray analysis software, normalized across chips using GCRMA followed by per gene normalization to median. For the purposes of this study, responses were defined as reduction in the serum paraprotein (or the urinary M protein in the absence of a serum M protein) of >=50% (PR), 25 to 49% (MR), increase of >=50% (PD) and stable disease for the remaining. Results: Five of the 30 patients had no response to the thalidomide Dexamethasone therapy. Using the class prediction tool available in Genespring (Support Vector Machines), we identified 25 genes that reliable predicted non responders (PD, NC) from the responders (MR, PR, and CR). See table for a list of predictive genes with identified genes. Conclusion: Using a combination of two datasets we have identified a set of genes that can be used to reliably predict lack of response to thalidomide and dexamethasone in patients with newly diagnosed MM. We think that this represents a step towards creation of custom microarrays spotted with genes that are capable of predicting lack of response (or response) for the purpose of tailoring therapy to the patient. Gene Predictive strength hypothetical protein FLJ20719 1.655 Tubulin alpha 6 1.653 SEC3-like 1 (S. cerevisiae) 1.649 Ribosomal protein L18 1.546 Ribosomal protein L4 1.432 Tubulin alpha 6 1.409 cleavage stimulation factor 1.393 Tubulin, alpha, ubiquitous 1.393 CD99 antigen 1.38 hmel2 1.346 Leptin receptor 1.291 Integrin-linked kinaseSMC4 structural maintenance of chromosomes 4-like 1 1.269 Cornichon homolog 1.255 Williams-Beuren syndrome chromosome region 5 1.217 Ubiquitin specific protease 1 1.2 Sarcoma antigen NY-SAR-91 1.2
Genomc-Wide Profiling of Gene Expression and DNA Copy Number Alterations in Multiple Myeloma.
Chapman, Mike, Carpten, John D. , Baker, Angela , Ahmann, Gregory , Trudel, Suzanne , Alsina, Melissa , Richardson, Paul G. , Auclair, Daniel , Trent, Jeffrey M. , Golub, Todd R. , Keats, Jonathan J. , Chng, Wee Joo , Siegel, David S. , Rajkumar, S. Vincent , Richardson, Paul Gerard Guy , Anderson, Kenneth C. , Perkins, Louise M. , Fonseca, Rafaël

Mayo Clinic

Blood | April 18, 2020 | Volume: 110 | Issue: 11 | Pages: 396-396

10.1182/blood.v110.11.396.396 Get It

Abstract In an effort to identify novel genetic abnormalities in multiple myeloma (MM) we analyzed an initial set, as part of the Multiple Myeloma Research Consortium (MMRC) Genomics Initiative, of 94 MM patient samples on high-resolution array-based comparative genomic hybridization (aCGH) and gene expression profiling (GEP) technologies. The MMRC Genomics Initiative is a three-year research program spanning a full-spectrum of genomic technologies with the goal of analyzing 250 MM patient samples by 2009. Raw data from the Initiative are released in near real time through the MMRC Multiple Myeloma Genomics Portal. This initial aCGH dataset from the Agilent 244K platform represents the highest resolution gene copy number analysis with corresponding GEP released to date in MM. It has confirmed the cytogenetic definitions of MM with the data set being split between patients with hyperdiploid and non-hyperdiploid MM. Furthermore, the 244K platform has helped to refine minimal regions of change present on 1p, 1q, 6q, 8p, 13q, 14q, and 16q. A comprehensive screen of the dataset for genes residing in regions of homozygous deletion identified 105 genes. The most commonly affected gene was CDKN2C(p18) (8.3%) while 12 other regions were recurrently targeted. Several of these regions were recently implicated in the pathogenesis of MM but the large majority represents novel observations. The aCGH and GEP data were integrated using two different programs developed by the core institutions (The Broad Institute of Harvard & MIT and Translational Genomics Research Institute). First, Genomic Identification of Significant Targets in Cancer (GISTIC), which identifies highly significant regions of change and a limited set of candidate genes within these regions, was used to identify 285 genes associated with DNA content alterations. Second, Breakpoint Expression Correlation (BEC), which identifies dysregulated genes on either side of a copy number alteration, was used to identify 194 genes with expression changes associated with a breakpoint. This latter gene list includes all known IgH translocation target genes identified to date in myeloma. Overlapping the gene lists generated by GISTIC, BEC, and the homozygous deletion screen identified a number of genes previously implicated in MM such as CDKN2C(p18), CYLD, BIRC2/BIRC3, and two novel genes, FAM46C and RNF6. Ongoing data integration with RNAi and high content sequencing projects of the current Initiative holds great promise in furthering our understanding of MM. The MMRC Genomics Initiative and resulting efforts from the myeloma research community will increase our understanding of MM at the molecular level, help to identify new targets, and ultimately lead to the development of better, more effective therapies for myeloma.
Gene Expression Profiling of Post-Follicular B-Cell Lymphoma
Kurtin, Paul J. , Remstein, Ellen D., Chng, Wee Joo , Huang, Gaofeng , Doǧan, Ahmet

Mayo Clinic

Blood | April 18, 2020 | Volume: 112 | Issue: 11 | Pages: 617-617

10.1182/blood.v112.11.617.617 Get It

Abstract Although classified as marginal zone lymphomas under the WHO classification, the molecular relationship between splenic marginal zone lymphoma (SMZL), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), and nodal marginal zone lymphoma (NMZL) has not been clarified. Furthermore, lymphoplasmacytic lymphoma (LPL) can show clinical morphologic and immunophenotypic overlap with these entities and may present a diagnostic challenge. In this analysis of gene expression data generated using the Affymetrix U133plus 2.0 chip from 32 SMZL, 25 MALTs (GI, salivary gland and lung), 23 NMZL and 25 LPL, we aim to identify the molecular relationship between these pathological entities using unsupervised methods, identify disease specific signatures and markers using supervised methods and also the functional implications of these signatures using a modified gene-set enrichment analysis. Using hierarchical clustering, MALT lymphoma forms a tight cluster regardless of tumor site. In addition, SMZL and NMZL form another large cluster. LPLs are divided into 2 main clusters with occasional samples interspersed amongst the SMZL and NMZL. There is no correlation between the percentage of CD20-positive B-cells, CD3-positive T-cells or CD138- positive plasma cells or tissue origin of the tumor and the way the samples are clustered. However, the separation of the LPLs into 2 major cluster correspond to the presence and absence of underlying Waldenstrom Macroglobulinaemia (WM), suggesting that the genes distinguishing the 2 clusters are potential markers for differentiating WM LPL from non-WM LPL. Next, using supervised analysis we identified a cluster of genes including MMP7, LTF and SFRP2 with high signals specific to MALTs, while other genes including PRDM1 (BLIMP1), XBP1 and TNFRSF17 (BCMA) were specifically over-expressed in LPL. These may therefore represent novel diagnostic marker differentiating these entities. Several of these are further validated at the protein level using immunohistochemistry on a tissue microarray. Consistent with the unsupervised analysis, SMZL and NMZL have little difference and share the over-expression of CD22 and WNT3 among other genes. Clustering of these samples based on the pathways and genesets that are enriched in the individual tumors as compared to their normal tissue counterpart showed a mutually exclusive pattern with significant enrichment of NFKB-related genesets and genes in LPL and MALT, and significant enrichment of B-cell receptor signaling genesets and genes in SMZL and NMZL. Our analysis, for the first time, describes the molecular relationship between these closely related lymphomas. In the process, we identified novel diagnostic markers that may differentiate these conditions and also new insights into molecular pathways that are differentially activated in the different conditions. These may represent potential therapeutic targets
Identification of Cellular Pathways Mediating Progression of Monoclonal Gammopathy (MGUS) to Multiple Myeloma (MM) Using Gene Expression Profiling (GEP).
Chng, Wee Joo , Huang, Gaofeng , Bergsagel, P. Leif , Fonseca, Rafaël

Mayo Clinic

Blood | April 18, 2020 | Volume: 112 | Issue: 11 | Pages: 1673-1673

10.1182/blood.v112.11.1673.1673 Get It

Abstract Events mediating transformation from pre-malignant MGUS to MM is currently not well defined. Recurrent genetic abnormalities such as t(11;14), t(4;14), hyperdiploidy and chromosome 13 deletion are already present in MGUS at relatively similar frequency to MM. The unified deregulation of D-type cyclins is also already present in MGUS. Previous GEP studies have revealed little differences between MGUS and MM. A more recent study using a large patient cohort and new generation Affymetrix genechip identifies an MGUS signature but the functional and biological significance underlying this signature is unknown. In the current study, we analyze a cohort of 22 MGUS and 101 MM from the Mayo Clinic with GEP performed on Affymetrix U133A genechip using gene set enrichment analysis, a method that analyze differentially expressed gene between 2 phenotypes of interest in the context of published or curated genesets that represent specific biological, chemical, or molecular perturbation to cells. This method increases the sensitivity of identifying low but significant changes in gene expression. We made further modification to the original method that allows assessment in individual samples rather than the average across a phenotype further increasing the specificity of the output. In this analysis, 313 genesets were significant enriched for genes over-expressed in MM compared to MGUS, representing potential activated pathways that mediate transformation. When MM samples and genesets were clustered using the enrichment score for each genesets and samples, 4 cluster of genesets emerged, one including a number of MYC genesets, one including a number of cell cycle related genesets, one including genesets related to metabolic activity and another including a number of IFN related genesets. Further dissection of these correlated genesets to identify common enriched genes (leading edge genes) led to identification of a MYC core signature, tRNA core signature, Proteosome core signature and metabolic core signature which are highly correlated. From known literature and biology, it is likely that MYC activation leads to downstream activation of protein synthesis (tRNA signature), degradation (proteasome signature), and metabolic pathway (metabolic signature). This is verified by GEP results from in vitro modulation of MYC activation in cell lines. In addition, a cell cycle core signature and IFN core signature was identified. Activation of IFN and MYC core signatures accounts for almost 90% of MM patients. The remaining patients have a metabolic signature without MYC or IFN activation. The activation of the different core signatures is significantly correlated with certain TC classes when assessed by Chi-Square test. IFN activation is significantly correlated with D1 subtypes and negatively correlated with D2 subtypes. MYC activation is negatively correlated with t(11;14). Similar patterns were observed in a validation dataset of 351 MM patients from UAMS (GSE2677) with GEP performed on the U133plus2.0 chip. These results are validated at the protein level using IHC on TMA of the Mayo cohort. The activation of the IFN and MYC pathway may represent predominant mechanism in MGUS to MM progression.
Immunoglobulin Light Chain Gene Constant Region Is An Invariable Part of Amyloid Deposits in AL Amyloidosis
Theis, Jason D. , Vrana, Julie A., Gamez, Jeffrey D., Zeldenrust, Stephen R., Dispenzieri, Angela , Doǧan, Ahmet

Mayo Clinic

Blood | April 18, 2020 | Volume: 112 | Issue: 11 | Pages: 3128-3128

10.1182/blood.v112.11.3128.3128 Get It

Abstract Background: Amyloidosis caused by immunoglobulin light chain (IGLC) deposition, so-called AL-type or primary amyloidosis, is the most common type of amyloidosis. It has been long believed that IGLC variable regions form the core of the AL-type amyloid deposits and peptides derived from IGLC constant region peptides are only occasionally integrated into this core. For this reason, the scientific effort to identify thge risk factors for development of AL amyloidosis and the biochemical characteristics amyloid deposits has focused on IGLC variable region derived proteins. To understand the peptide constituents of AL amyloidosis better, we undertook a comprehensive study of AL amyloidosis using a novel mass spectrometry based proteomic analysis approach. Methods: Paraffin embedded tissue from 100 cases of AL amyloidosis was studied. In each case amyloid type was previously established by clinical and pathological examination. Congo red stained paraffin sections were prepared and amyloid deposits were microdissected by laser microdissection microscopy. The microdissected tissue fragments were processed and trypsin digested into peptides. The peptides were analyzed by nano-flow liquid chromatography electrospray tandem mass spectrometry (LC-MS/MS). The resulting LC-MS/MS data were correlated to theoretical fragmentation patterns of tryptic peptide sequences from the Swissprot database using Scaffold (Mascot, Sequest, and X!Tandem search algorithms). Peptide identifications were accepted if they could be established at greater than 90.0% probability and protein identifications were accepted if they could be established at greater than 90.0% probability and contain at least 2 identified spectra. The identified proteins were subsequently examined for the presence or absence of amyloid related peptides. Results and Discussion: LC-MS/MS gave peptide profiles consistent with AL amyloidosis in each case. The analysis showed IGLC-lambda deposition in 66 cases and IGLC-kappa deposition in 34 of cases. In each case, LC MS/MS confirmed the previous clinicopathological diagnosis. Interestingly peptides representing IGLC constant region were present in each case. Using this LC-MS/MS methodology, theoretically it is possible to cover 78% of the IGLC-lambda and 87% IGLC-kappa constant regions. In our samples, the average coverage of the IGLC-lambda and IGLC-kappa constant regions were 40% (range 14–78%)and 55% (range 16–87%) respectively. Additionally, the distribution of the peptides suggested that in the majority of the cases whole of the IGLC constant region was deposited. LC MS/MS also identified IGLC-lambda variable region peptides in 37 of 66 cases and IGLC-kappa variable region peptides in 29 of 34 cases studied. The variable region coverage was more restricted and the peptides identified were frequently within the framework segments. It is likely that the peptides derived from CDR segments were present but not detected by the methodology as somatic hypermutation randomly alters the amino acid sequence in the CDR segments and such new sequences are not available in public databases used by algorithms for peptide identification. In the cases with the IGLC variable region hits, it was also possible to assign variable region family usage. IGLC-lambda cases frequently used IGLC-lambda variable region I, II and III families whereas, in IGLC-kappa cases, IGLC-kappa variable region I and III families dominated. Conclusions: AL amyloidosis can be accurately diagnosed using laser microdissection and LC-MS/MS based proteomic analysis in routine clinical specimens. AL amyloidosis invariably contains IGLC constant region peptides and, frequently, the whole of the constant region is deposited. This finding suggests that studies on molecular pathogenesis of amyloidosis should not only consider the IGLC-variable region but also the constant region. It is possible to identify IGLC variable region family usage in AL amyloidosis using LC MS/MS based proteomic analysis. In the clinical setting, this information may be helpful in predicting organ distribution and clinical outcome.
Genomic Complexity and Recurrent Aberration in Multiple Myeloma: Analysis of a Compendium of aCGH and Gene Expression Profiles.
Jiménez‐Zepeda, Víctor H. , Chng, Wee Joo , Lee, Ian , Braggio, Esteban , Keats, Jonathan J. , Bergsagel, P. Leif , Fonseca, Rafaël

Mayo Clinic

Blood | April 18, 2020 | Volume: 112 | Issue: 11 | Pages: 1682-1682

10.1182/blood.v112.11.1682.1682 Get It

Abstract Multiple Myeloma (MM) is the second most prevalent haematological disorder in the US with great recent progress propelled by various technological and therapeutic advances. Nevertheless, the complexity of MM genomes remains inadequately characterized. We have combined high-resolution (44K Agilent) array comparative genomic hybridization (aCGH) and gene expression data with clinical outcomes in an initial attempt at indexing genomic complexity in MM and its clinical implication in 100 MM patients. We enumerated the Number of Aberrations per Tumor (NAPT) as defined by the ADM-1 algorithm available within CGH Analytics. There appear to be no difference in degree of genetic complexity between hyperdiploid and non-hyperdiploid myeloma. Generally, t(11;14) have low NAPT whereas D2 tumors have high NAPT. Amongst the high-risk genetic subtypes, tumors with maf translocations have relatively low NAPT whereas t(4;14) have high NAPT. Whilst a Multivariate Cox Proportional Hazards regression of survival outcome showed little statistical support for popular indicators such as ploidy and TC classification, results for NAPT were considerably more encouraging (p~ 0.07, median survival of 40 months in low complexity vs 18 months in high). Log-rank tests further supported prognosis based on NAPT independent of clinical status and ploidy. To characterize complexity, we clustered aCGH profiles by clinical status, ploidy and TC classification. Clear patterns of aggregation and recurrent aberration were observed suggesting that they were possibly instrument to aberrant gene expression. Indeed, expression of a large proportion of genes approximately 2Mb of the recurrent breakpoints varied significantly between patients carrying aberrations vis-a-viz others that did not. Comparison against known gene sets showed an enrichment for cell-cycle and apoptosis genes. We are presently characterizing several such breakpoint-associated genes for their functional significance.
Inactivation of Tumor Necrosis Factor 3 Gene (TRAF3) Is Frequently Identified in Waldenström’s Macroglobulinemia Patients.
Wier, Scott Van, Price-Troska, Tammy, Henderson, Kimberly J., Chesi, Marta , Carpten, John D. , Bergsagel, Leif P., Braggio, Esteban , Keats, Jonathan J. , Bergsagel, P. Leif , Fonseca, Rafaël

Mayo Clinic

Blood | April 18, 2020 | Volume: 110 | Issue: 11 | Pages: 2476-2476

10.1182/blood.v110.11.2476.2476 Get It

Abstract Constitutive activation of NF-κB signaling pathways has been identified in a variety of malignancies, however the molecular basis has remained largely unknown. Recently, we have shown mutations in 10 genes encoding positive and negative regulators of NF-κB signaling pathways in 20% of multiple myeloma (MM) patients, with TRAF3 being the most commonly affected gene. TRAF3 is a negative regulator of NF-κB signal and its inactivation results in the constitutive activation of the alternative or noncanonical NF-κB signaling pathway. With the exception of two recent studies in MM, there is no available data regarding the mechanisms that dysregulate NF-κB in other B-cell malignancies. The aim of this study was to analyze the TRAF3 status in a cohort of Waldenström’s macroglobulinemia (WM) patients. Forty-nine WM were analyzed by using a combination of array-based comparative genomic hybridization (aCGH) and cIgM-FISH. Genome sequencing from 28 of these patients was performed on all coding exons of TRAF3 and the adjacent intron-exon junctions. A NF-κB index, as a measure of NF-κB transcription activity, was calculated from 21 patients with gene expression data. The index is the mean expression level of four probe sets differentially expressed between human myeloma cell lines with identified mutations compared to those without identified NF-κB pathway mutations (CD74, IL2RG and 2x TNFAIP3). By performing aCGH we identified a small monoallelic deletion (∼460 Kb), including the TRAF3 locus in one of 22 patients. Genome sequencing identified a missense mutation (D483N) in the remaining allele. This substitution affects a highly conserved amino acid throughout vertebrate evolution, suggesting its functional relevance. We used cIgM-FISH to screen 27 patients with no available aCGH data and we found one biallelic TRAF3 deletion and one chromosome 14 monosomy. In the later case, no DNA was available to sequence the remaining allele. Both samples with biallelic inactivation of TRAF3 possess the two highest NFKB index values of our WM cohort, suggesting NF-κB transcription activity. Moreover, the case with biallelic deletion showed the lowest level of TRAF3 gene expression. Additionally, the entire TRAF3 coding region was sequenced in 28 of these 49 patients and one homozygous nonsense mutation (K286X) was identified. No GEP was available in this sample to calculate the NF-κB index. TRAF3 was only recently implicated in a malignant process, when inactivating mutations and biallelic deletions were reported in approximately 13% of MM patients, making it the most frequently inactivated tumor suppressor in MM. Our study has identified biallelic TRAF3 inactivation in at least 3 of 49 WM patients, suggesting that the constitutive activation of NF-κB signaling pathways may be involved in the pathogenesis of WM. Recent findings showing an association between TRAF3 loss of function and good response to bortezomib in MM patients suggest that proteasome inhibitor-based therapy may be an attractive option in the treatment of the WM patients with constitutive activation of NF-κB signaling pathways. Additional mutational screening of TRAF3 and other regulators of these pathways are ongoing to determine the extent of constitutive activation present in WM and other B-cell malignancies.
Acquired Pure Red Cell Aplasia Associated with Clonal T-Cell Receptor (TCR) Gene Rearrangements with and without Pathologic Features of T-Cell Large Granular Lymphocytic Leukemia (T-LGLL).
Nowakowski, Grzegorz S. , Morice, William G. , Tefferi, Ayalew , Phyliky, Robert E., Morice, William George , Phyliky, Robert L.

Mayo Clinic

Blood | April 18, 2020 | Volume: 104 | Issue: 11 | Pages: 2819-2819

10.1182/blood.v104.11.2819.2819 Get It

Abstract Acquired pure red cell aplasia (APRCA) is associated with a number of conditions including malignancies, infections and autoimmune disorders. APRCA also occurs in patients with T-LGLL. It is postulated that suppression of erythropoiesis in T-LGLL is related to the immune destruction of erythroid precursors by the LGL clone. We hypothesize that APRCA can be associated with clonal T-cell expansion without pathological evidence of T-LGLL. Methods: We identified patients who were diagnosed with APRCA and had clonal TCR gene rearrangements. Clinical course, bone marrow pathology and flow cytometry data were reviewed. Immunohistochemical studies were performed on available bone marrow biopsies using antibodies to CD3, CD8, CD20 and the cytotoxic granule proteins TIA-1 and granzyme B. Clonal TCR gene rearrangements were detected by PCR and Southern blot. The diagnosis of APRCA was based on the absence of erythroid progenitors, with intact granulo- and thrombopoiesis. A pathologic diagnosis of T-LGL leukemia was established by the presence of clonal TCR gene rearrangements and an immunophenotypically distinct CD8 positive T-cell population as previously described. The diagnostic flow cytometric features included abnormal patterns of T-cell antigen expression and aberrant co-expression of NK-cell antigens. Immunoperoxidase features supportive of a diagnosis of LGL were the presence of interstitial clusters or intravascular staining of cells positive for CD8 and TIA-1 and/or granzyme B. Results: We identified 28 patients with APRCA and the presence of clonal TCR gene rearrangements seen at Mayo Clinic Rochester between 7/1/1991 to 6/1/03. All patients presented with a transfusion dependent anemia (median hemoglobin 7.8 g/dL, range 3.6–10.3). Tissue was available for immunohistochemical studies for 21 cases. 13 of 21 patients (61%) had an immunophenotypically abnormal T-cell population which, in conjunction with the clonal TCR gene rearrangements were considered diagnostic of T-LGL. 8 patients (39%) had no pathological evidence of T-LGLL despite clonal TCR gene rearrangement studies. The most commonly used treatment consisted of oral cyclophosphamide which was used in 14 of 21 patients (8 and 6 in patients with and without pathological evidence of T-LGLL respectively). A normalization of hemoglobin was seen in 11 patients (6 and 5 in patients with and without evidence of T-LGLL respectively). Median duration of response was 30 months (range 22–120). None of 8 patients with APRCA and clonal TCR gene rearrangements without evidence of LGLL at the the time of initial diagnosis developed overt T-LGLL during follow up (median 64 months, range 30–118). Discussion: 39 % of patients with APRCA and evidence of clonal TCR gene rearrangements did not meet pathological criteria for diagnosis of T-LGLL. There was no apparent difference in disease presentation and response to therapy in patients with or without pathological evidence of LGLL. The significance of the presence of clonal TCR gene rearrangements in the absence of a detectable immunophenotypically abnormal T-cell population is unclear. It is possible that T-LGL was present which could not be detected by our analyses. Alternatively, the clonal TCR gene rearrangements could be indicative of a pertubation of the T-cell compartment related to an autoimmune disorder causing the APRCA. The fact that none of the patients developed progression to overt LGLL supports the latter possibility.
Methylation of the Tumor Suppressor Gene PTPRO (Receptor-Type Protein Tyrosine Phosphatase) Is Associated with Expression of Important Apoptosis-Related Proteins in Chronic Lymphocytic Leukemia (CLL).
Motiwala, Tasneem , Ghoshal, Kalpana , Majumder, Sarmila , Kutay, H, Kitada, Shinichi, Reed, John C. , Dewald, G, Tallman, M. A., Liu, Tongyu, Plass, Christoph , Lucas, David , Byrd, John C., Jacob, Samson T., Grever, Michael R. , Neuberg, Donna , Flinn, Ian W. , Byrd, John C.

Mayo Clinic

Blood | April 18, 2020 | Volume: 104 | Issue: 11 | Pages: 2804-2804

10.1182/blood.v104.11.2804.2804 Get It

Abstract We previously demonstrated that apoptosis-inhibiting proteins (e.g., Bcl-2, Mcl-1, and XIAP) are important in predicting response to chemotherapy and antibody therapy for CLL. Additionally, genetic abnormalities and epigenetic control of gene expression have become increasingly important in understanding the prognosis and potential therapeutic opportunities in this disease. Greater than 80% of patients with CLL have genetic abnormalities detectable by FISH. Important subsets include those with a less favorable prognosis (deletions of 17p, 11q), an intermediate prognosis (trisomy 12), or a favorable outcome (deletion of 13q). PTPRO, encoding a receptor-type tyrosine phosphatase, is a specific tumor suppressor gene located in chromosomal region 12p12.3. PTPRO has been highly characterized as inhibiting anchorage-independent tumor growth in human lung carcinomas. This gene has been found to be silenced by promoter methylation, and can be re-expressed by hypomethylating agents in human lung tumor models. Thus, we examined the methylation profile of the promoter region of PTPRO in primary leukemic cells from patients with CLL, and in B cells obtained from normal volunteers. Analysis of the PTPRO CpG island by methylation-specific PCR and combined bisulfite restriction analysis (COBRA) demonstrated that this region was methylated in 91% of samples from 46 patients, whereas it was unmethylated in control B cells from normal volunteers. Specific quantitative determinations of important proteins related to apoptosis in the leukemic cells from 20 of these patients showed that, in the group with methylation of the PTPRO promoter, there was a significant elevation of Bcl-2 (p=0.079), Mcl-1 (p=0.004), XIAP (p=0.048), Bcl-2/BAX ratio (p=0.0024), and Mcl-1/BAX ratio (p=0.0017). There was no apparent relationship with FISH category or immunoglobulin VH mutational status. Thus, PTPRO promoter methylation analysis may identify a subset of CLL patients less likely to respond to therapy, and provide a potential reversible target for new therapeutic approaches to this disease. Finally, analysis of methylation of CLL samples by restriction landmark genome scanning also revealed methylation of genes for three additional protein tyrosine phosphatases: PTPRN2, PTPRZ2, and PTPN11. Increases in methylation of two of these (PTPRN2 and PTPRZ2) in CLL samples relative to control B cells was confirmed by COBRA. These results provide additional potential molecular targets for CLL therapy.